Oxigenador de membrana extracorpóreo en 12 casos de shock cardiogénico tras cirugía cardiaca

Moreno, Iván Sánchez; Soria, A.; Gómez, A. López; Vicente, R.; Porta, Juan Ignacio Dalmau; Vicente, J. L.; Barberá, M.

doi:10.1016/s0034-9356(11)70023-8

Cited by 8 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients requiring ECMO have unstable physiology, with multiorgan failure either as a result of the primary disease leading to the requirement for ECMO or as a result of when the critical state is complicated by nosocomial infections. ( 13 ) Additionally, ECMO use can be an important contributor to ECMO-related systemic inflammation. ( 14 ) The presence of acquired infections in ECMO patients has a 50% associated mortality rate.…”

Section: Discussionmentioning

confidence: 99%

Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study

López-Sánchez¹,

Moreno-Puigdollers

Rubio-Lopez³

et al. 2020

Revista Brasileira De Terapia Intensiva

View full text Add to dashboard Cite

Objective To determine micafungin plasma levels and pharmacokinetic behavior in patients treated with extracorporeal membrane oxygenation. Methods The samples were taken through an access point before and after the membrane in two tertiary hospitals in Spain. The times for the calculation of pharmacokinetic curves were before the administration of the drug and 1, 3, 5, 8, 18 and 24 hours after the beginning of the infusion on days one and four. The area under the curve, drug clearance, volume of distribution and plasma half-life time with a noncompartmental pharmacokinetic data analysis were calculated. Results The pharmacokinetics of the values analyzed on the first and fourth day of treatment did not show any concentration difference between the samples taken before the membrane (Cin) and those taken after the membrane (Cout), and the pharmacokinetic behavior was similar with different organ failures. The area under the curve (AUC) before the membrane on day 1 was 62.1 (95%CI 52.8 - 73.4) and the AUC after the membrane on this day was 63.4 (95%CI 52.4 - 76.7), p = 0.625. The AUC before the membrane on day 4 was 102.4 (95%CI 84.7 - 142.8) and the AUC was 100.9 (95%CI 78.2 - 138.8), p = 0.843. Conclusion The pharmacokinetic parameters of micafungin were not significantly altered.

show abstract

Section: Discussionmentioning

confidence: 99%